



Effective 10/25/2026

Lines Of Business All Lines of Business

COVID-19 Vaccine and Administration

DISCLAIMER

This policy is intended to provide a general reference regarding billing, coding and documentation guidelines. Coding methodology, regulatory requirements, industry standard claims editing logic, benefit design and other factors are considered in developing payment policies. This policy is intended to serve as a guideline only and does not constitute medical advice, any guarantee of payment, plan pre-authorization, an explanation of benefits, or a contract. This policy does not govern whether a specific procedure is covered under any specific member plan or policy, nor is it intended to address every claim situation. The determination that any service, procedure, item, etc., is covered under a member's benefit plan shall not be construed as a determination that a provider will be reimbursed for services provided. Individual claims may be affected by other factors, including but not necessarily limited to state and federal laws and regulations, legislative mandates, provider contract terms, and THP's professional judgment.

Reimbursement for any services shall be subject to member benefits and eligibility on the date of service, medical necessity, adherence to plan policies and procedures, claims editing logic, provider contractual agreement, and applicable referral, authorization, notification and utilization management guidelines. Unless otherwise noted within the policy, THP's policies apply to both participating and non-participating providers and facilities. THP reserves the right to review and revise these policies periodically as it deems necessary in its discretion, and it is subject to change or termination at any time by THP. THP has full and final discretionary authority for its interpretation and application. Accordingly, THP may use reasonable discretion in interpreting and applying this policy to health care services provided in any particular case. No part of this policy may be reproduced, stored in a retrieval system or transmitted, in any shape or form or by any means, whether electronic, mechanical, photocopying or otherwise, without express written permission from THP. When printed, this version becomes uncontrolled. For the most current information,

refer to the following website: healthplan.org.

DEFINITIONS, ACRONYMS, TERMS

Term	Definition
Bureau for Medical Services (BMS)	BMS is the designated single state agency responsible for the administration of the State of West Virginia's Medicaid program.
Centers for Medicare and Medicaid Services (CMS)	A federal agency that provides health coverage to people through Medicare, Medicaid, the Children's Health Insurance Program, and the Health Insurance Marketplace.
COVID-19	Coronavirus disease 2019 (COVID-19) is an infectious respiratory illness caused by a virus called SARS-CoV-2.
Emergency Use Authorization (EUA)	An authority that allows the Food and Drug Administration (FDA) to help strengthen the nation's public health protections against chemical, biological, radiological and nuclear (CBRN) threats by facilitating the availability and use of medical counter measures (MCMs) needed during public health emergencies (PHE).
Federally Qualified Health Center (FQHC)	FQHCs are outpatient clinics that qualify for specific reimbursement systems under Medicare and Medicaid.
Medicare Administrative Contractor (MAC)	A Medicare Administrative Contractor (MAC) is a private health care insurer that has been awarded a geographic jurisdiction to process Medicare Part A and Part B (A/B) medical claims or Durable Medical Equipment (DME) claims for Medicare Fee-For-Service (FFS) beneficiaries. They are the primary operational contact between the Medicare FFS program and the health care providers enrolled in the program.
Rural Health Clinic (RHC)	RHCs are rurally located medical clinics providing healthcare services to patients in underserved areas.

POLICY

COVID-19 Vaccines are covered under both the medical and pharmacy benefit, meaning a member may receive the COVID-19 vaccine in a practitioner's office or pharmacy.

The COVID-19 vaccine and administration codes listed below either have full FDA approval or are approved under the FDA's Emergency Use Authorization (EUA).

COVID-19 vaccines will be covered with no member cost sharing for vaccines administered.

Mountain Health Trust (MHT) Only: Administration of the vaccine is not covered.

Billing Information

When COVID-19 vaccines are provided by the government at no charge, practitioners are required to only bill for the vaccine administration.

Practitioners must bill the product-specific vaccine administration code with a COVID-19

diagnosis.

If the sole purpose of the practitioner visit is to administer a COVID-19 vaccine, practitioners should not bill an evaluation and management (E&M) code. Practitioners may bill an E&M code if a medically necessary, significant, and separately identifiable E&M is performed on the same visit as a vaccine administration, by adding modifier 25 to the E&M code and including the appropriate diagnosis code(s) on the claim.

- **Federally Qualified Health Centers (FQHCs) and Rural Health Clinics (RHCs) only:**
 - When administering the vaccine, with no other service performed on the same date of service (DOS), bill the product-specific vaccine administration code from the table below as an 837 p (professional) claim.
 - When performing any other encounter-related service on the same date of service as the vaccine administration, bill the following to receive the applicable encounter rate plus the vaccine administration reimbursement:
 - The encounter-related service as an 837 i (institutional) claim.
 - The product-specific vaccine administration code as an 837 p (professional) claim.

Approved COVID-19 Vaccine Codes

CPT Code	Labeler Name	Description
90480	-	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, single dose
91304	Novavax	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5mL dosage, for intramuscular use
91318	Pfizer	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 3 mcg/0.2 mL dosage, tris-sucrose formulation, for intramuscular use
91319	Pfizer	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 10 mcg/0.2 mL dosage, tris-sucrose formulation, for intramuscular use
91320	Pfizer	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use
91321	Moderna	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, 25 mcg/0.25 mL dosage, for intramuscular use
91322	Moderna	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, 50 mcg/0.5 mL dosage, for intramuscular use

M0235	-	IV Infusion Monoclonal Antibody Prod Noc First Dose. Covid-19 Monoclonal Antibody products and administration
M0236	-	IV Infusion Monoclonal Antibody Prod Noc Second Dose. Covid-19 Monoclonal Antibody products and administration
Q0235	-	Injection Monoclonal Antibody Noc 1MG. Covid-19 hospitalized patients post exposure prophylaxis or tx od covid. Adult or pediatric.

Not Approved COVID-19 Vaccine Codes

91302	Astra Zeneca	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOx1) vector, preservative free, 5x10 ¹⁰ viral particles/0.5mL dosage, for intramuscular use
-------	--------------	---

Approved COVID-19 Vaccine Administration Codes

CPT Code	Labeler Name	Description
0041A	Novavax	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/ 0.5mL dosage; first dose
0042A	Novavax	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/ 0.5mL dosage; second dose
0044A	Novavax	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/ 0.5mL dosage Booster
M0201	N/A	Covid-19 vaccine administration inside a patient's home; reported only once per individual home per date of service when only covid-19 vaccine administration is performed at the patient's home

Not Approved COVID-19 Vaccine Administration Codes

0021A	Astra Zeneca	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOx1) vector, preservative free, 5x10 ¹⁰ viral particles/0.5mL dosage; first dose.
0022A	Astra Zeneca	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

	(coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOx1) vector, preservative free, 5x10 ¹⁰ viral particles/0.5mL dosage; second dose	
--	--	--

REFERENCES

Centers for Medicare and Medicaid Services (CMS). COVID-19 Vaccines and Monoclonal Antibodies. Last modified February 2, 2023. Available at: <https://www.cms.gov/medicare/medicare-part-b-drug-average-sales-price/covid-19-vaccines-and-monoclonal-antibodies>

FDA Approves First COVID-19 Vaccine. U.S. Food and Drug Administration. Available at: <https://www.fda.gov/news-events/press-announcements/fda-approves-first-covid-19-vaccine>

Toolkit on COVID-19 Vaccine: Health Insurance Issuers and Medicare Advantage Plans. Centers for Medicare and Medicaid Services. Available at: <https://www.cms.gov/files/document/COVID-19-toolkit-issuers-MA-plans.pdf>

Centers for Medicare and Medicaid Services (CMS). MLN Connects 2022-07-14-MLNC. July 14, 2022. Accessed July 14, 2022. https://www.cms.gov/outreach-and-education/outreachffsprovpartprogprovider-partnership-email-archive/2022-07-14-mlnc#_Toc108597545

United States Food and Drug Administration (FDA). Coronavirus Disease 2019 (COVID-19) EUA: Vaccines. Accessed July 13, 2022. <https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization#vaccines>

Centers for Medicare and Medicaid (CMS). What do I need to know? CMS Waivers, Flexibilities, and the Transition Forward from the COVID-19 Public Health Emergency. Published February 27, 2023.

United States Food and Drug Administration. FAQs: What happens to EUAs when a public health emergency ends? Updated January 31, 2023.

United States Department of Health and Human Services. Fact Sheet: COVID-19 Public Health Emergency Transition Roadmap. Published February 9, 2023.

Centers for Medicare and Medicaid (CMS). Vaccine Pricing: COVID-19 Vaccines and Monoclonal Antibodies. Last modified August 17, 2023.

United State Food and Drug Administration (FDA). FDA News Release. Coronavirus (COVID-19) Update: FDA Authorizes Changes to Simplify Use of Bivalent mRNA COVID-19 Vaccines. April 18, 2023. <https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-changes-simplify-use-bivalent-mrna-covid-19-vaccines>

United State Food and Drug Administration (FDA). Janssen COVID-19 Vaccine. June 2, 2023. <https://www.fda.gov/vaccines-blood-biologics/coronavirus-covid-19-cber-regulated-biologics/janssen-covid-19-vaccine>

Centers for Medicare and Medicaid (CMS). MLNConnects 2023-08-17-MLNC. COVID-19: CPT Codes for Vaccines No Longer Authorized. August 17, 2023. <https://www.cms.gov/outreach-and-education/outreach/ffsprovpartprog/provider-partnership-email-archive/75730954/>

2023-08-17-mlnc#_Toc143093084

Centers for Medicare and Medicaid (CMS). MLNConnects 2023-09-14-OCE. COVID-19: Updated mRNA Vaccines for Patients 6 Months & Older. September 14, 2023. <https://www.cms.gov/training-education/medicare-learning-network/newsletter/2023-09-14-oce>